CD8+CD28+/CD8+CD28− T cell equilibrium can predict the active stage for patients with inflammatory bowel disease

The CD8+CD28+/CD8+CD28− T cell balance, expected to be a novel immunologic marker, presented a satisfactory efficiency with high sensitivity and specificity in predicting the active stage in UC and CD patients, and the balance was closely related to the use of BAs and surgery.